5-year survival rates based on the type of leukemia in Iran, a Meta-analysis

Predictors of self-perceived burden among patients with cancer in Hebei, China

INTRODUCTION

Cancer is the leading cause of death worldwide. Both new cancer cases and deaths are rising annually. The high cost of cancer treatment and the guilt of being dependent on family members for a long time lead to patients with cancer's self-perceived burden (SPB). Previous studies have shown that different countries, populations, and cancer stages have different SPB levels. SPB is a psychological stressor, the high SPB may affect the medical treatment process and decision-making of patients with cancer, which may cause patients to refuse treatment and seriously cause suicidal ideation.

OBJECTIVE

This study aimed to determine the level of SPB and its predictors among patients with cancer in the Fourth Hospital of Hebei Medical University, China.

METHODS

A cross-sectional study of 977 patients with cancer was recruited by simple random sampling. A self-administered questionnaire was used. Multiple linear regression was used to investigate the predictors of SPB.

RESULTS

A total of 566 respondents participated in the study, with a response rate of 58.4%. A total of 88.0% had moderate to severe SPB. The mean ± standard deviation of SPB was 67.75 ± 15.69. The predictors of SPB were parents as caregivers, siblings as caregivers, occupational status before illness, duration of cancer, impact of cancer on the patient's mobility, treatment of cancer (radiation and chemotherapy), type of cancer, stage of cancer, and coping strategies (confrontation, resignation, and fantasy).

CONCLUSION

The prevalence of SPB is considered high, therefore, healthcare professionals should pay high attention to reducing the SPB of patients with cancer in clinical nursing work. It is recommended that effective intervention measures be implemented to lower the suicide rate among patients with cancer ultimately.

Priority setting for improved leukemia management and research in South Africa: a modified Delphi study

PURPOSE

In resource-limited environments, setting priorities for leukemia care becomes essential to ensure effective and efficient use of available resources. This study aimed to identify the key areas of leukemia care and services by determining their prioritization within the South African healthcare system and developing a set of improvement and research priorities.

METHODS

A two-round modified Delphi method was used to identify leukemia care priorities and rank areas of leukemia management improvement and research priorities. Healthcare professional experts comprised of Clinical Hematologists and Hematopathologists. In round 1, participants independently rated the importance of 125 iterative statements on leukemia care and services derived from literature. In round 2, agreement within the expert participants was considered to finalize the list of priority statements and 17 improvement and research priorities were ranked based on level of importance.

RESULTS

In total, a list of 67 priority statements reached consensus, and 17 improvement and research priorities were established. A high agreement (≥ 90%) was reached for 24 statements within the six themes, these included accurate and advanced diagnostic techniques, factors in determining treatment strategies (e.g., risk stratification), supportive care measures (e.g., pain management and infection prevention), ensuring adequate healthcare workforce, and creating multidisciplinary teams. The highest ranked improvement and research priorities were timely delivery of diagnosis and treatments and biomarker development for early detection, prognosis, and treatment response.

CONCLUSION

This study identified key priorities for leukemia care within the South African healthcare system, providing an evidence-based framework through expert consensus.

Regional and national burden of leukemia and its attributable burden to risk factors in 21 countries and territories of North Africa and Middle East, 1990-2019: results from the GBD study 2019

PURPOSE

Regional and national data on leukemia's burden provide a better comprehension of leukemia's trends and are vital for policy-makers for better allocation of the resources. This study reports the burden of leukemia, and the attributed burden to its risk factors in 21 countries and territories of the North Africa and Middle East.

METHODS

Data from cancer registration, scientific literature, survey, and reports were the input to estimate the burden of leukemia. In addition, the burden of attributable risk factors with evidence of causation with leukemia was calculated using the comparative risk assessment framework. All measures are reported as counts and rates divided by sex and specific age groups.

RESULTS

In 2019, there were 39,297 (95% uncertainty interval: 32,617-45,056) incident cases of leukemia with an age-standardized rate (ASR) of 7.8 (6.5-8.8) per 100,000 in the region. There were also 25,143 (21,109-28,826) deaths and 1,011,555 (822,537-1,173,621) DALYs attributed to Leukemia with an ASR of 5.4 (4.6-6.1) per 100,000 and 183.4 (150.7-211.2) per 100,000, respectively. Years of life lost (YLLs) (179.4 [147.2-206.7]) were accountable for the major part of DALYs. All count measures increased, while all the ASRs decreased during 1990-2019. The Syrian Arab Republic, Qatar, and Afghanistan had the highest ASR incidence, mortality, and DALYs rate in 2019. Incidence, DALYs, and prevalence rates were higher in males of all age groups except under five, and the highest rates were observed in +75 age group. Four major risk factors for leukemia were smoking, high body mass index, occupational exposure to benzene, and formaldehyde.

CONCLUSION

Despite the reduction in age-standardized rates of incidence and mortality, the burden of leukemia has increased steadily, due to population growth and aging. Notable variations exist between age-standardized rates in region's countries.

Relapse, Mortality, and the Associated Factors in Children with Acute Lymphoblastic Leukemia; A Competing Risks Analysis

Background: Acute lymphoblastic leukemia (ALL) is the most frequent form of malignant neoplasia diagnosed in ages 0 to 14 years old. Efforts have not yet converted into a better prospect. Bone marrow relapse is still the leading cause of person-year of life lost in this malignancy. Objectives: This study aimed at identifying the associated risk factors for relapse and mortality for pediatric patients with ALL in standard and high-risk groups. Methods: This study included a cohort of pediatric (0 - 16 years old) patients with ALL referred to Sheikh Hospital, Mashhad, Iran from 2007 to 2016. The demographic, clinical, and laboratory information were considered. Hazard ration (HR) with 95% highest posterior density region was obtained, using a Bayesian competing risks model. Results: Of 424 patients with a mean age of 5.56 ± 3.75 years, 172 (40%) were female. Median follow-up time was 43.29 months, 10.6% had a relapse, and 17.2% had mortality related to ALL. Relapse-free survival rates at 1, 3, and 5 years were 97, 91, and 88%, respectively. Overall survival rates were 86, 83, and 82%, respectively. In the standard-risk group, tumor lysis syndrome (TLS) significantly increased either the relapse risk [HR: 13.47 (2.05 - 67.54)] or mortality risk [HR: 19.57 (2.24 - 32.18)]. In the high-risk group, the higher level of hemoglobin, platelet, and lactic acid dehydrogenase was significantly associated with higher relapse risk. TLS was associated with a higher risk of mortality in high-risk groups. Conclusions: It was suggested that TLS was a predictor for the disease relapse as well as mortality in pediatric patients with ALL. However, further evaluation on the larger population of patients is demanded to ascertain the precision of such parameters in leukemic management strategies.

Leukemia incidence trends at the global, regional, and national level between 1990 and 2017

Background

Leukemias are a group of life-threatening malignant disorders of the blood and bone marrow. The incidence of leukemia varies by pathological types and among different populations.

Methods

We retrieved the incidence data for leukemia by sex, age, location, calendar year, and type from the Global Burden of Disease online database. The estimated average percentage change (EAPC) was used to quantify the trends of the age-standardized incidence rate (ASIR) of leukemia from 1990 to 2017.

Results

Globally, while the number of newly diagnosed leukemia cases increased from 354.5 thousand in 1990 to 518.5 thousand in 2017, the ASIR decreased by 0.43% per year. The number of acute lymphoblastic leukemia (ALL) cases worldwide increased from 49.1 thousand in 1990 to 64.2 thousand in 2017, whereas the ASIR experienced a decrease (EAPC = - 0.08, 95% CI - 0.15, - 0.02). Between 1990 and 2017, there were 55, 29, and 111 countries or territories that experienced a significant increase, remained stable, and experienced a significant decrease in ASIR of ALL, respectively. The case of chronic lymphocytic leukemia (CLL) has increased more than twice between 1990 and 2017. The ASIR of CLL increased by 0.46% per year from 1990 to 2017. More than 85% of all countries saw an increase in ASIR of CLL. In 1990, acute myeloid leukemia (AML) accounted for 18.0% of the total leukemia cases worldwide. This proportion increased to 23.1% in 2017. The ASIR of AML increased from 1.35/100,000 to 1.54/100,000, with an EAPC of 0.56 (95% CI 0.49, 0.62). A total of 127 countries or territories experienced a significant increase in the ASIR of AML. The number of chronic myeloid leukemia (CML) cases increased from 31.8 thousand in 1990 to 34.2 thousand in 2017. The ASIR of CML decreased from 0.75/100,000 to 0.43/100,000. A total of 141 countries or territories saw a decrease in ASIR of CML.

Conclusions

A significant decrease in leukemia incidence was observed between 1990 and 2017. However, in the same period, the incidence rates of AML and CLL significantly increased in most countries, suggesting that both types of leukemia might become a major global public health concern.